HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2007-0161v1 25/9/2158    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abraham, M. Articles by Peled, A. Search for Related Content PubMed PubMed Citation Articles by Abraham, M. Articles by Peled, A.

CANCER STEM CELLS

Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F-Benzoyl-TN14003

^aGoldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel;
^bBone Marrow Transplantation Department, Chaim Sheba Medical Center, Tel-Hashomer, Israel

Key Words. CXCR4 • Mobilization • Hematopoietic stem cells • Hematopoietic progenitors

Correspondence: Amnon Peled, Ph.D., Hadassah Hebrew University Hospital, Gene Therapy Institute, P.O. Box 12000, Jerusalem, 91120 Israel. Telephone: 972-2-677-8780; Fax: 972-2-643-0982; e-mail: peled{at}hadassah.org.il

Received March 6, 2007; accepted for publication May 15, 2007.
First published online in STEM CELLS EXPRESS   May 24, 2007.



An increase in the number of stem cells in blood following mobilization is required to enhance engraftment after high-dose chemotherapy and improve transplantation outcome. Therefore, an approach that improves stem cell mobilization is essential. The interaction between CXCL12 and its receptor, CXCR4, is involved in the retention of stem cells in the bone marrow. Therefore, blocking CXCR4 may result in mobilization of hematopoietic progenitor and stem cells. We have found that the CXCR4 antagonist known as 4F-benzoyl-TN14003 (T-140) can induce mobilization of hematopoietic stem cells and progenitors within a few hours post-treatment in a dose-dependent manner. Furthermore, although T-140 can also increase the number of white blood cells (WBC) in blood, including monocytes, B cells, and T cells, it had no effect on mobilizing natural killer cells. T-140 was found to efficiently synergize with granulocyte colony-stimulating factor (G-CSF) in its ability to mobilize WBC and progenitors, as well as to induce a 660-fold increase in the number of erythroblasts in peripheral blood. Comparison between the CXCR4 antagonists T-140 and AMD3100 showed that T-140 with or without G-CSF was significantly more potent in its ability to mobilize hematopoietic stem cells and progenitors into blood. These results demonstrate that different CXCR4 antagonists may have different therapeutic potentials.

Disclosure of potential conflicts of interest is found at the end of this article.

This article has been cited by other articles:

				R. M. Lemoli and A. D'Addio Hematopoietic stem cell mobilization Haematologica, March 1, 2008; 93(3): 321 - 324. [Full Text] [PDF]